Stryker Corporation (NYSE:SYK) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share guidance of $6.45-6.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.43. Stryker Corporation also updated its Q3 guidance to $1.50-1.55 EPS.
Stryker Corporation (NYSE SYK) opened at 146.53 on Monday. The stock has a 50 day moving average price of $142.76 and a 200-day moving average price of $134.44. The firm has a market cap of $54.81 billion, a P/E ratio of 32.71 and a beta of 0.80. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $148.84.
Stryker Corporation (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, topping the consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The company had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.98 billion. During the same quarter in the previous year, the firm posted $1.39 earnings per share. Stryker Corporation’s revenue for the quarter was up 6.1% on a year-over-year basis. Equities research analysts forecast that Stryker Corporation will post $6.50 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be paid a $0.425 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.16%. Stryker Corporation’s dividend payout ratio is 37.95%.
Several analysts recently weighed in on the stock. BMO Capital Markets reissued a hold rating and issued a $125.00 price objective on shares of Stryker Corporation in a research note on Tuesday, April 11th. Jefferies Group LLC reaffirmed a hold rating and set a $132.00 price target on shares of Stryker Corporation in a research report on Thursday, April 13th. BidaskClub cut shares of Stryker Corporation from a buy rating to a hold rating in a research report on Monday, July 31st. Barclays PLC reaffirmed a sell rating and set a $133.00 price target on shares of Stryker Corporation in a research report on Thursday, April 27th. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $148.00 price target on shares of Stryker Corporation in a research report on Monday, April 17th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $144.03.
In related news, insider David Floyd sold 19,305 shares of the company’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total value of $2,790,730.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 7.40% of the company’s stock.
WARNING: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://stocknewstimes.com/2017/08/07/stryker-corporation-syk-releases-fy17-earnings-guidance-updated.html.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
